HomeLantheus Holdings Inc.

Lantheus Holdings Inc.

aPROMISE Receives CE Mark Reports EXINI Diagnostics AB (Subsidiary of Lantheus Holdings)

aPROMISE includes a solution for automated body segmentation and marking, quantifying and reporting suspicious lesions in their anatomical context. The AI tool provides enhanced consistency in quantitative analysis and is intended to increase efficiency, accuracy and reproducibility of PSMA PET/CT image assessments.

Lantheus Holdings Announces FDA Clearance for AI-Enabled Automated Bone Scan Index (aBSI) in Prostate Cancer on GE Healthcare’s Xeleris Platform

Sr. Vice President of Lantheus Holdings Corporate Development Etienne Montagut said, “Lantheus is delighted by the U.S. approval of our digital AI solution for prostate cancer, aBSI, on GE Healthcare’s platform.

New Data on Novel Cardiac PET Imaging Agent LMI 1195 in Development for the Diagnostic Assessment of Ischemic Heart Failure Patients at Risk for Sudden Cardiac Death

Presented at at ACC.18. Findings Show LMI 1195 Provides a Comparable Measure of Cardiac Sympathetic Nerve Function as PET imaging with C11 HED